Jim Simons’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $42.4M | Sell |
440,712
-15,700
| -3% | -$1.57M | 0.07% | 368 |
|
|
2025
Q4 | $44.4M | Sell |
456,412
-32,350
| -7% | -$2.78M | 0.07% | 322 |
|
|
2025
Q3 | $34.8M | Sell |
488,762
-3,050
| -0.6% | -$203K | 0.05% | 483 |
|
|
2025
Q2 | $29.4M | Sell |
491,812
-9,900
| -2% | -$543K | 0.04% | 549 |
|
|
2025
Q1 | $26.3M | Sell |
501,712
-11,300
| -2% | -$635K | 0.04% | 553 |
|
|
2024
Q4 | $28.2M | Sell |
513,012
-26,486
| -5% | -$1.39M | 0.04% | 507 |
|
|
2024
Q3 | $27.1M | Sell |
539,498
-20,714
| -4% | -$956K | 0.04% | 536 |
|
|
2024
Q2 | $24.6M | Sell |
560,212
-13,032
| -2% | -$554K | 0.04% | 509 |
|
|
2024
Q1 | $25.2M | Sell |
573,244
-6,968
| -1% | -$308K | 0.04% | 535 |
|
|
2023
Q4 | $27.5M | Buy |
580,212
+5,300
| +0.9% | +$223K | 0.04% | 491 |
|
|
2023
Q3 | $25.5M | Sell |
574,912
-7,500
| -1% | -$348K | 0.04% | 474 |
|
|
2023
Q2 | $27.8M | Buy |
582,412
+1,800
| +0.3% | +$81.2K | 0.04% | 523 |
|
|
2023
Q1 | $22.8M | Sell |
580,612
-13,700
| -2% | -$498K | 0.03% | 647 |
|
|
2022
Q4 | $16.8M | Sell |
594,312
-32,200
| -5% | -$921K | 0.02% | 814 |
|
|
2022
Q3 | $18.8M | Sell |
626,512
-46,066
| -7% | -$1.6M | 0.03% | 706 |
|
|
2022
Q2 | $22.8M | Sell |
672,578
-734
| -0.1% | -$26.3K | 0.03% | 661 |
|
|
2022
Q1 | $30.2M | Sell |
673,312
-20,000
| -3% | -$925K | 0.04% | 537 |
|
|
2021
Q4 | $32M | Sell |
693,312
-9,400
| -1% | -$379K | 0.04% | 483 |
|
|
2021
Q3 | $23.6M | Buy |
702,712
+400
| +0.1% | +$13.6K | 0.03% | 603 |
|
|
2021
Q2 | $20.7M | Sell |
702,312
-21,302
| -3% | -$587K | 0.03% | 747 |
|
|
2021
Q1 | $18.6M | Sell |
723,614
-14,543
| -2% | -$347K | 0.02% | 814 |
|
|
2020
Q4 | $16.8M | Buy |
738,157
+13,600
| +2% | +$314K | 0.02% | 843 |
|
|
2020
Q3 | $15.5M | Buy |
724,557
+38,200
| +6% | +$858K | 0.02% | 871 |
|
|
2020
Q2 | $15.9M | Buy |
686,357
+60,200
| +10% | +$1.29M | 0.01% | 950 |
|
|
2020
Q1 | $13.4M | Buy |
626,157
+91,789
| +17% | +$2.19M | 0.01% | 981 |
|
|
2019
Q4 | $12.5M | Buy |
534,368
+117,268
| +28% | +$2.74M | 0.01% | 1306 |
|
|
2019
Q3 | $8.77M | Buy |
417,100
+53,700
| +15% | +$1.1M | 0.01% | 1468 |
|
|
2019
Q2 | $7.43M | Buy |
363,400
+17,200
| +5% | +$405K | 0.01% | 1592 |
|
|
2019
Q1 | $9.72M | Buy |
346,200
+25,700
| +8% | +$673K | 0.01% | 1399 |
|
|
2018
Q4 | $7.84M | Buy |
320,500
+121,800
| +61% | +$3.27M | 0.01% | 1453 |
|
|
2018
Q3 | $7.38M | Buy |
198,700
+81,500
| +70% | +$2.2M | 0.01% | 1550 |
|
|
2018
Q2 | $2.43M | Buy |
117,200
+63,742
| +119% | +$1.13M | ﹤0.01% | 2165 |
|
|
2018
Q1 | $770K | Buy |
53,458
+5,688
| +12% | +$81K | ﹤0.01% | 2759 |
|
|
2017
Q4 | $724K | Buy |
47,770
+31,870
| +200% | +$405K | ﹤0.01% | 2786 |
|
|
2017
Q3 | $153K | Buy |
+15,900
| New | +$151K | ﹤0.01% | 3047 |
|
|
2017
Q2 | – | Sell |
-18,618
| Closed | -$166K | – | 3272 |
|
|
2017
Q1 | $166K | Sell |
18,618
-7,682
| -29% | -$71.2K | ﹤0.01% | 3023 |
|
|
2016
Q4 | $292K | Sell |
26,300
-19,600
| -43% | -$211K | ﹤0.01% | 2918 |
|
|
2016
Q3 | $780K | Buy |
+45,900
| New | +$850K | ﹤0.01% | 2673 |
|
Other funds holding IRMD
CCM
VCM
NTCM
Jim Simons's IRMD Position: Q1 2026 in Review
Jim Simons reduced its iRadimed (IRMD) stake by 3.4% in Q1 2026, selling an estimated $1.57M and leaving 440,712 shares worth $42.4M. The position accounts for 0.07% of the portfolio, ranked #368.
Jim Simons first reported a position in IRMD in Q3 2016 and has held it in 38 quarters since. The position peaked at $44.4M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Jim Simons held 440,712 shares of iRadimed worth $42.4M as of Q1 2026.
- Jim Simons sold 15,700 iRadimed shares in Q1 2026, an estimated $1.57M.
- iRadimed made up 0.07% of Jim Simons's portfolio in Q1 2026, its #368 holding.
- Jim Simons first reported a position in iRadimed in Q3 2016 and has held it in 38 quarters since.
- Jim Simons's iRadimed position peaked at $44.4M in Q4 2025.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.